Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine

Vaccine

Volumn 25, Issue 9, 2007, Pages 1676-1682

  Johansson, Jeannette ^a   Hellman, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Allergy; IgE; Therapeutic vaccines

Indexed keywords

DIMER; FREUND ADJUVANT; HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOLOGICAL ADJUVANT; MINERAL OIL; MONOMER; MONTANIDE 51; PROTEIN ORO; PROTEIN ORORO; PROTEIN ORRORO; PROTEIN ORRRORO; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

AGONIST; ALLERGY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN VARIANT; RAT; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOANTIBODIES; DIMERIZATION; FREUND'S ADJUVANT; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; MANNITOL; OLEIC ACIDS; OPOSSUMS; RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

EID: 33846211443     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.10.055     Document Type: Article

References (30)

1. Johansson J., Ledin A., Vernersson M., Lovgren-Bengtsson K., and Hellman L. Identification of adjuvants that enhance the therapeutic antibody response to host IgE. Vaccine 22 21-22 (2004) 2873-2880
2. Vernersson M., Ledin A., Johansson J., and Hellman L. Generation of therapeutic antibody responses against IgE through vaccination. FASEB J 16 8 (2002) 875-877
3. Ledin A., Bergvall K., Hillbertz N.S., Hansson H., Andersson G., Hedhammar A., et al. Generation of therapeutic antibody responses against IgE in dogs, an animal species with exceptionally high plasma IgE levels. Vaccine 24 1 (2006) 66-74
4. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 1 (2006) 49-55
5. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199 (2004) 201-216
6. Fehr T., Skrastina D., Pumpens P., and Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci USA 95 16 (1998) 9477-9481
7. Lechner F., Jegerlehner A., Tissot A.C., Maurer P., Sebbel P., Renner W.A., et al. Virus-like particles as a modular system for novel vaccines. Intervirology 45 4-6 (2002) 212-217
8. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20 25-26 (2002) 3104-3112
9. Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol 24 (1994) 415-420
10. Aveskogh M., and Hellman L. Evidence for an early appearance of modern post-switch isotypes in mammalian evolution; cloning of IgE, IgG and IgA from the marsupial Monodelphis domestica. Eur J Immunol 28 9 (1998) 2738-2750
11. Hellman L., Pettersson U., and Bennich H. Characterization and molecular cloning of the mRNA for the heavy (epsilon) chain of rat immunoglobulin E. Proc Natl Acad Sci USA 79 4 (1982) 1264-1268
12. Kohfeldt E., Maurer P., Vannahme C., and Timpl R. Properties of the extracellular calcium binding module of the proteoglycan testican. FEBS Lett 414 3 (1997) 557-561
13. Kohfeldt E., Sasaki T., Gohring W., and Timpl R. Nidogen-2: a new basement membrane protein with diverse binding properties. J Mol Biol 282 1 (1998) 99-109
14. Vernersson M., Aveskogh M., and Hellman L. Cloning of IgE from the echidna (Tachyglossus aculeatus) and a comparative analysis of epsilon chains from all three extant mammalian lineages. Dev Comp Immunol 28 1 (2004) 61-75
15. Talwar G.P., Singh O., Pal R., Chatterjee N., Sahai P., Dhall K., et al. A vaccine that prevents pregnancy in women. Proc Natl Acad Sci USA 91 18 (1994) 8532-8536
16. Renard V., Sonderbye L., Ebbehoj K., Rasmussen P.B., Gregorius K., Gottschalk T., et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 171 3 (2003) 1588-1595
17. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17 7 (1999) 666-669
18. Waterston A.M., Salway F., Andreakos E., Butler D.M., Feldmann M., and Coombes R.C. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer 90 6 (2004) 1279-1284
19. Hertz M., Mahalingam S., Dalum I., Klysner S., Mattes J., Neisig A., et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 167 7 (2001) 3792-3799
20. Waterston A.M., Gumbrell L., Bratt T., Waller S., Gustav-Aspland J., L'Hermenier C., et al. Phase I study of TNFalpha AutoVaccine in patients with metastatic cancer. Cancer Immunol Immunother 54 9 (2005) 848-857
21. Goodnow C.C., Crosbie J., Adelstein S., Lavoie T.B., Smith-Gill S.J., Brink R.A., et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334 6184 (1988) 676-682
22. Fulcher D.A., Lyons A.B., Korn S.L., Cook M.C., Koleda C., Parish C., et al. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J Exp Med 183 5 (1996) 2313-2328
23. Goodnow C.C., Sprent J., Fazekas de St Groth B., and Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435 7042 (2005) 590-597
24. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 5 (2004) 497-505
25. Bergfors E. Aspects of pertussis, pertussis vaccination and adverse events associated with aluminium adsorbed vaccines. PhD Thesis, Gothenburg, Sweden: Gothenburg University, 2005; ISBN: 91-628-6714-8.
26. Vrtala S., Hirtenlehner K., Susani M., Hufnagl P., Binder B.R., Vangelista L., et al. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy Immunol 118 2-4 (1999) 218-219
27. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101 Suppl. 2 (2004) 14677-14682
28. Linhart B., Jahn-Schmid B., Verdino P., Keller W., Ebner C., Kraft D., et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 16 10 (2002) 1301-1303
29. Linhart B., Hartl A., Jahn-Schmid B., Verdino P., Keller W., Krauth M.T., et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 115 5 (2005) 1010-1016
30. Linhart B., and Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 134 4 (2004) 324-331